Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 5.42 USD -2.34% Market Closed
Market Cap: 206.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

TRDA Price Targets Summary
Entrada Therapeutics Inc

Wall Street analysts forecast TRDA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRDA is 18.87 USD with a low forecast of 17.17 USD and a high forecast of 21 USD.

TRDA Lowest Forecast
Wall Street Target
17.17 USD
217% Upside
TRDA Average Forecast
Wall Street Target
18.87 USD
248% Upside
TRDA Highest Forecast
Wall Street Target
21 USD
287% Upside
Lowest
Price Target
17.17 USD
217% Upside
Average
Price Target
18.87 USD
248% Upside
Highest
Price Target
21 USD
287% Upside
Entrada Therapeutics Inc Competitors:
Price Targets
NGNE
Neurogene Inc
181% Upside
PHARM
Pharming Group NV
407% Upside
VLA
Valneva SE
62% Upside
4
4BB
4Basebio PLC
111% Upside
NGNE
Neurogene Inc
181% Upside
PHARM
Pharming Group NV
407% Upside
VLA
Valneva SE
62% Upside
4
4BB
4Basebio PLC
111% Upside
PRAX
Praxis Precision Medicines Inc
144% Upside
6160
Beigene Ltd
6% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
34% Upside
002252
Shanghai RAAS Blood Products Co Ltd
7% Upside

Revenue
Forecast

Revenue Estimate
Entrada Therapeutics Inc

The compound annual growth rate of Entrada Therapeutics Inc's revenue for the next 3 years is -35%.

N/A
Past Growth
-35%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Entrada Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Entrada Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
20%
Average Beat
What are analyst estimates?

See Also

Summary
TRDA intrinsic value, competitors valuation, and company profile.
DCF Valuation
TRDA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TRDA stock valuation using valuation multiples.
Wall Street Estimates
TRDA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TRDA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TRDA's stock price target?
Price Target
18.87 USD

According to Wall Street analysts, the average 1-year price target for TRDA is 18.87 USD with a low forecast of 17.17 USD and a high forecast of 21 USD.

What is Entrada Therapeutics Inc's Revenue forecast?
Projected CAGR
-35%

The compound annual growth rate of Entrada Therapeutics Inc's revenue for the next 3 years is -35%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.